In a study with rats, researchers tested dexmedetomidine to see how it affects outcomes in sepsis. They induced sepsis in the rats and then divided them into groups receiving either saline (group C), midazolam (group M), or dexmedetomidine (group D). They found that rats in the dexmedetomidine group had lower TNF-α levels and better survival rates compared to the other groups. Dexmedetomidine also improved kidney function, reduced caspase-3 expression in spleen tissues, and increased ubiquitin expression. Overall, it was shown that dexmedetomidine can boost survival rates during sepsis in rats.